Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
DRIVE-IDDS, an integrated drug discovery solution: a complete continuum from target to clinical candidate
Home . Service . DRIVE-IDDS: integrated drug discovery solution
DRIVE-IDDS, a premium integrated offer for the whole discovery process
Discovering new drugs and therapeutic solutions is becoming increasingly hard, as candidates and tests are sought ever faster while clinical losses must be reduced. The discovery process requires multiple and highly specialized skills, the combination of which is rare to find in a single structure.
DRIVE-IDDS, a premium integrated offer comprised of highly specialized experts providing access to innovative technology platforms covering the entire drug discovery process.
DRIVE-IDDS is a complete continuum of discovery, from target to clinical candidate, for:
new chemical entities – DRIVE-Small Molecule
Targeted radiopharmaceutical products – DRIVE-MRT
DRIVE-Small Molecule brings together the right skills, expertise and discovery platforms to design and deliver new clinical chemical entities in therapeutic areas such as oncology, immuno-oncology, and immuno-inflammation
A simpler set-up with several possible choices to quickly identify and validate new promising chemical series (hits) – thanks to our technologies and those developed by our strategic partners, HitGen, 2Bind, Icaria et Iktos.
Multi-disciplinary teams with expertise in medicinal chemistry, in vitro and in vivo pharmacology, and DMPK/Bioanalysis, as well as experience in the discovery process, to streamline the time frames and multi-parameter optimization cycles of the Hit-to-Lead, Lead Optimisation and pre-clinical candidate selection until submission of the IND.
DRIVE-Small Molecule, a way to drastically speed up your new chemical entities.
DRIVE-Molecular RadioTherapy encompasses all the skills, experience and technological platforms needed to generate new targeted radiopharmaceutical products in clinical oncology.
Oncodesign and its strategic partners Covalab, CheMatech and ABX-CRO mobilize all their expertise to streamline, design and optimize targeted and effective radiopharmaceutical agents against specific cancers, to demonstrate the preclinical proof of concept, safety margin and guidance for a clinical development path.
An agile and flexible “one-stop shop” solution that works in stages from Hit to IND: a single Oncodesign point of contact coordinates your entire program
Agility, flexibility, and an ability to innovate
A collaborative culture rooted in the company and its practices
The pharmaceutical culture, the quality and the expertise of a team of experienced and dedicated scientists to successfully complete your project.
An efficient and proactive transfer of information, data, and technologies between partners to save time between the different development phases of your project. An big bonus compared to collaboration methods involving several individual CROs.
A unique project management model with trusted partners and a reduced administrative burden thanksto the integrated model
Personal project management tailored to your needs and challenges. . Regular discussions and exchanges through project meetings and steering committees so you can make your decisions within the given deadlines.